Global patterns of health care for acute coronary syndromes

Current Opinion in Cardiology

Volumn 19, Issue 6, 2004, Pages 625-630

  Sirinaeve, Peter R ^a   Van De Werf, Frans J ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Acute coronary syndrome; Global; Guidelines

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

CLINICAL PRACTICE; CLINICAL TRIAL; CULTURAL FACTOR; DOSE RESPONSE; DRUG USE; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; GEOGRAPHY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDICAL PRACTICE; OUTCOMES RESEARCH; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; REVIEW; SOCIAL ASPECT;

ACUTE DISEASE; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; DELIVERY OF HEALTH CARE; HUMANS; INTERNATIONALITY; LENGTH OF STAY; MYOCARDIAL INFARCTION; SYNDROME;

EID: 8344273482     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000142063.30214.d2     Document Type: Review

References (43)

1. Bertrand ME, Simoons ML, Fox KA, et al.: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002, 23:1809-1840.
2. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002, 40:1366-1374.
3. Ryan TJ, Antman EM, Brooks NH, et al.: Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Committee on Management of Acute Myocardial Infarction. J Am Coll Cardiol 1999, 34:890-911.
4. Van de Werf FJ, Ardissino D, Betriu A, et al.: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003, 24:28-66.
5. Peterson ED, Pollack CV Jr, Roe MT, et al.: Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 2003, 42:45-53. This paper describes the impact on outcome of differences in adherence to guidelines within the United States.
6. Van de Werf FJ, Topol EJ, Lee KL, et al.: Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries: results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. JAMA 1995, 273:1586-1591.
7. White H: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001, 358:1855-1863.
8. Simes J, White H, Marschner I, et al.: International differences in patients, care and outcomes associated with acute myocardial infarction: the HERO-2 trial. Heart Lung Circ 2003, 12:A23.
9. Giugliano RP, Llevadot J, Wilcox RG, et al.: Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis: results from InTIME-II. Eur Heart J 2001, 22:1702-1715.
10. Kramer JM, Newby LK, Chang WC, et al.: International variation in the use of evidence-based medicines for acute coronary syndromes. Eur Heart J 2003, 24:2133-2141. This paper describes regional differences in the management of acute coronary syndromes in both SYMPHONY trials.
11. Llevadot J, Giugliano RP, Antman EM, et al.: Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Eur Heart J 2001, 22:2104-2115.
12. Khot UN, Khot MB, Bajzer CT, et al.: Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904. Analyzing data for more than 120,000 patients in 14 international clinical trials of coronary artery disease, the authors found that patterns of conventional risk factors did not vary significantly across different continents.
13. O'Shea JC, Califf RM: International differences in cardiovascular clinical trials. Am Heart J 2001, 141:866-874.
14. Fox KA, Goodman S, Bigonzi F, et al.: Inter-regional differences and outcome in unstable angina: analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events. Eur Heart J 2000, 21:1433-1439.
15. Ross AM, Gao R, Coyne KS, et al.: A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J 2001, 142:244-247.
16. Fox KA, Goodman SG, Klein W, et al.: Management of acute coronary syndromes: variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002, 23:1177-1189.
17. Fox KA, Goodman SG, Anderson FA, et al.: From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003, 24:1414-1424. Using serial data from the international GRACE registry, this paper describes global impact of guidelines on the management of acute coronary syndromes.
18. Sanborn TA, Jacobs AK, Frederick PD, et al.: Comparability of quality-of-care indicators for emergency coronary angioplasty in patients with acute myocardial infarction regardless of on-site cardiac surgery (report from the National Registry of Myocardial Infarction). Am J Cardiol 2004, 93:1335-1339.
19. Hasdai D, Behar S, Wallentin L, et al.: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin: the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002, 23:1190-1201.
20. Gupta M, Chang WC, Van de Werf FJ, et al.: International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2. Eur Heart J 2003, 24:1640-1650. The authors analyzed the regional impact of evidence-based treatments on outcome for patients with acute MI.
21. Steg PG, Goldberg RJ, Gore JM, et al.: Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002, 90:358-363.
22. Bonnefoy E, Lapostolle F, Leizorovicz A, et al.: Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002, 360:825-829.
23. Andersen HR, Nielsen TT, Rasmussen K, et al.: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003, 349:733-742.
24. Widimsky P, Groch L, Zelizko M, et al.: Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000, 21:823-831.
25. Widimsky P, Budesinsky T, Vorac D, et al.: Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003, 24:94-104.
26. Cannon CP, Gibson CM, Lambrew CT, et al.: Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000, 283:2941-2947.
27. Goldberg RJ, Steg PG, Sadiq I, et al.: Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol 2002, 89:791-796.
28. Liao L, Whellan DJ, Tabuchi K, Schulman KA: Differences in care-seeking behavior for acute chest pain in the United States and Japan. Am Heart J 2004, 147:630-635.
29. Wallentin L, Goldstein P, Armstrong PW, et al.: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135-142.
30. Budaj A, Brieger D, Steg PG, et al.: Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003, 146:999-1006. In this GRACE registry subanalysis, the authors found striking regional differences in the use of proven antithrombotic therapies in patients with acute coronary syndromes.
31. Klein W, Kraxner W, Hodl R, et al.: Patterns of use of heparins in ACS: correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 2003, 90:519-527. The preference for either unfractionated heparin or LMWH varies globally and is associated with outcome, according to this analysis from the GRACE database.
32. Steg PG, lung B, Feldman LJ, et al.: Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT. Eur Heart J 2003, 24:613-622.
33. Fox KA, Cokkinos DV, Deckers J, et al.: The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 2000, 21:1440-1449.
34. Akkerhuis KM, Deckers JW, Boersma E, et al.: Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes: results from PURSUIT. Eur Heart J 2000, 21:371-381.
35. Yusuf S, Flather M, Pogue J, et al.: Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998, 352:507-514.
36. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000, 36:970-1062.
37. Kaul P, Newby LK, Fu Y, et al.: International differences in evolution of early discharge after acute myocardial infarction. Lancet 2004, 363:511-517. The authors compared international patterns in length of stay after MI, using data from GUSTO-I and III and ASSENT-2. Although overall length of stay appeared to decrease over time, the length of hospitalization was found to be consistently higher in European countries.
38. Shibata MC, Flather MD, de Arenaza DP, et al.: Potential impact of socioeconomic differences on clinical outcomes in international clinical trials. Am Heart J 2001, 141:1019-1024.
39. Orlandini A, Pieper K, Armstrong P, et al.: Different outcomes in patients with ST-elevation myocardial infarction among countries with different gross national income [abstract]. Eur Heart J 2003, 24:300.
40. Levy E, Gabriel S, Dinet J: The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003, 21:651-659.
41. Akinboboye O, Idris O, Akinboboye O, Akinkugbe O: Trends in coronary artery disease and associated risk factors in sub-Saharan Africans. J Hum Hypertens 2003, 17:381-387.
42. Nishtar S: Prevention of coronary heart disease in south Asia. Lancet 2002, 360:1015-1018.
43. Montalescot G, Van de Werf FJ, Gulba DC, et al.: Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the Global Registry of Acute Coronary Events (GRACE). Catheter Cardiovasc Interv 2003, 60:360-367.